Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

Leukemia

Volumn 16, Issue 11, 2002, Pages 2190-2196

  Hochhaus, A ^a   Kreil, S ^a   Corbin, A S ^b   La Rosee P ^a,b   Muller M C ^a   Lahaye, T ^a   Hanfstein, B ^a   Schoch, C ^c   Cross, N C P ^d   Berger, U ^a   Gschaidmeier, H ^e   Druker, B J ^b   Hehlmann, R ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e Novartis Pharma GmbH   (Germany)

Author keywords

BCR ABL; Chronic myelogenous leukemia; Imatinib; Resistance; STI571

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; CYTOSTATIC AGENT; IMATINIB; ONCOPROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLAST CELL CRISIS; CHIMERA; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DOSE RESPONSE; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; KARYOTYPING; MOLECULAR CLONING; MOLECULAR MECHANICS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0036850514     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402741     Document Type: Article

References (36)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
2. Melo JV. The molecular biology of chronic myeloid leukaemia. Leukemia 1996; 10: 751-756.
3. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Niederwieser D, O'Brien SG, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL. Glivec™ (imatinib mesylate) induces hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase II study. Blood 2002; 99: 1928-1937.
4. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller C, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MWN, Fischer T, O'Brien SG, Stone R, Gambacorti-Passerini C, Russell N, Reiffers J, Shea T, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ. Glivec™ (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-3539.
5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
6. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Fernandez Reese S, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
7. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, on behalf of the International STI571 CML Study Group. Imatinib mesylate (Gleevec™) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloid leukemia in chronic phase: results of a phase II study. N Engl J Med 2002; 346: 645-652.
8. Tipping AJ, Mahon FX, Lagarde V, Goldman JM, Melo JV. Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood 2001; 98: 3864-3867.
9. Mahon FX, Deininger MWN, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070-1079.
10. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95: 3498-3505.
11. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Cambarcorti-Passerini C. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95: 1758-1766.
12. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000; 289: 1938-1942.
13. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
14. Hochhaus A, Kreil S, Corbin A, La Rosée P, Lahaye T, Berger U, Cross NCP, Linkesch W, Druker BJ, Hehlmann R. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293: 2163a.
15. Barthe C, Cony-Makhoul P, Melo JV, Reiffers J, Mahon FX. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293: 2163a.
16. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472-3475.
17. Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG, Koeffler HP. Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002; 99: 1860-1862.
18. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487-491.
19. Cross NCP, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186-189.
20. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53-59.
21. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NCP, Hochhaus A. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825-1832.
22. Cross NCP, Feng L, Bungey J, Goldman JM. Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. Leuk Lymphoma 1993; 11 (Suppl. 1): 39-43.
23. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994; 269: 22925-22928.
24. Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW. Identification of CRKL as the constitutively phosphorylated 39- kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994; 84: 2912-2918.
25. ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia + leukemia. Blood 1994; 84: 1731-1736.
26. Heaney C, Kolibaba K, Bhat A, Oda T, Ohno S, Fanning S, Druker BJ. Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation. Blood 1997; 89: 297-306
27. Senechal K, Heaney C, Druker B, Sawyers CL. Structural requirements for function of the CrkI adapter protein in fibroblasts and hematopoietic cells. Mol Cell Biol 1998; 18: 5082-5090.
28. Corbin AS, Buchdunger E, Pascal F, Druker BJ. Analysis of the structural basis of specificity of STI571 binding to the Abl kinase domain. J Biol Chem published 20 June 2002 as 10.1074/jbc.M111525200.
29. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ, Lydon NB. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-104.
30. Saraste M, Sibbald PR, Wittinghofer A. The P-loop - a common motif in ATP- and GTP-binding proteins. Trends Biochem Sci 1990; 15: 430-434.
31. Shah NP, Nicoll JM, Gorre ME, Paquette RL, Ford J, Sawyers CL. Resistance to Gleevec: Sequence analysis reveals a spectrum of BCR/ABL kinase domain mutations in both acquired- and de novo-resistant cases of chronic myelogenous leukemia (CML) in myeloid blast crisis. Blood 2001; 98 (Supp. 1): 770a.
32. Dorey K, Engen JR, Kretzschmar J, Wilm M, Neubauer G, Schindler T, Superti-Furga G. Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene 2001; 20: 8075-8084.
33. Duesberg P, Stindl R, Hehlmann R. Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortment catalyzed by aneuploidy. Proc Natl Acad Sci USA 2001; 98: 11283-11288.
34. Chase A, Huntly BJP, Cross NCP. Cytogenetics of chronic myeloid leukemia. Best Pract Res Clin Haematol 2001; 14: 553-571.
35. Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Koeffler HP, Ottmann OG. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 2002; 359: 481-486.
36. La Rosée P, O'Dwyer ME, Druker BJ. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia 2002; 16: 1213-1219.